MGST1

Across TCGA pan-cancer cohorts, MGST1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MGST1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MGST1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MGST1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where MGST1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.131	0.861	.001	35	view →
HNSC	OS	Quartile	All	0.755	0.967	.002	17	view →
PDAC	DFS	Quartile	All	0.679	0.958	.001	11	view →
GBM	OS	Median	All	0.809	0.896	.016	6	view →
LUAD	OS	Quartile	III,IV	1.000	0.354	.027	6	view →
LSCC	OS	Tertile	All	1.000	0.934	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MGST1–CCRCC (DFS)

Open the CCRCC breakdown →